It's that time again, folks -- and, no, I'm not talking about air-conditioner weather.

Last week (on May 15), the deadline was hit for money managers with more than $100 million in asset under management to file Form 13F with the Securities and Exchange Commission. Form 13F lists all the holdings of prominent investment funds and hedge funds as of March 31, which essentially allows Wall Street and investors a look under the hood, so to speak, to see what the top money managers have been up to during the first quarter of 2019. This inside peek can alert investors to trends within a sector or industry and can help determine overall market sentiment.

Over the next couple of years, there are few if any industries expected to rival the "green rush" in terms of sales growth potential. Following the legalization of recreational marijuana in Canada, as well as 33 U.S. states giving cannabis the OK from a medical standpoint, the sky is the limit for budding pot stocks.

Then again, the potential of the legal weed industry is no secret to Wall Street professionals or long-term investors. If you had the foresight (and luck) to invest in any of the "Big Three" marijuana stocks at the beginning of 2016 -- Canopy Growth, Aurora Cannabis, or Cronos Group -- you'd be up by somewhere between 2,000% and 7,000% today.

You might think that the choice between Aphria (NYSE:APHA) and Aurora Cannabis (NYSE:ACB) is an easy one. Aphria underperformed Aurora last year and has done the same in 2019 so far -- and by a wide margin.

But there's a lot more to consider than just past stock performance in choosing between Aphria and Aurora. Which of these two Canadian marijuana stocks is the better pick now? Here's how Aphria and Aurora stack up against each other.

Chances are you'd struggle to find an industry creating more metaphorical and literal buzz right now than marijuana. After lurking in the shadows for decades, the cannabis industry has had the proverbial green carpet rolled out in Canada, where recreational weed is now legal, and in 33 U.S. states where medical cannabis has been legalized in some capacity. The sky looks to be the limit for the cannabis industry.

Unfortunately, the sky has also been the limit for the traditional fundamental metrics used to gauge the value of publicly listed companies. Just as shaking a pinball machine sends it into "tilt," a thorough review of the underlying fundamentals of most pot stocks would probably cause investors' brains to "tilt."

The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) and Blissco Cannabis Corp. (“Blissco”) (CSE: BLIS) (

Canada's recreational marijuana market is valued at over $5 billion Canadian ($3.71 billion) per year, and that means that leading marijuana stocks are poised to see sales skyrocket following legalization last October.

To make sure it gets its fair share of this opportunity, Aurora Cannabis (NYSE:ACB) has been pouring money into acquisitions and greenhouse expansion.

Earlier this week, management reported quarterly financial results showing its strategy is paying off with rapid revenue growth. But the results also show the company has a long way to go before it turns a profit. Here are eight facts you need to know following the company's fiscal third-quarter update.

The S&P/TSX Composite Index is 2.5% below its highs at the time of writing today, as the broad market selloff continues.

With this, we are seeing increasingly nervous investors that are becoming more aware of the risks out there and less willing to overlook them.

As far as risk goes, the cannabis industry is certainly fraught with it, if only for the reason that this industry is new, so there will be growing pains, unexpected setbacks, and increased volatility in this growth stage.

Primarily known for operating dispensaries in Florida, Trulieve Cannabis Corp. (CSE: TRUL) today announced plans to expand into Connecticut by acquiring an existing storefront. 

Trulieve just entered an agreement to snap up 100% of Bristol-based medical cannabis dispensary The Healing Corner, which has operated in the city since 2014.  

Medical marijuana usage was officially legalized in Connecticut back in 2012. While various bills have been proposed to legalize recreational usage in both 2018 and early 2019, none of them have yet gathered enough support to be passed and hit the governor’s desk. 

Canadians have been able to buy marijuana for recreational use since last October, and that's creating a massive opportunity for cannabis companies, including Tilray (NASDAQ:TLRY).

Tilray reported its latest quarterly earnings earlier this week, and while sales are soaring, so too are its expenses. Here are five facts you should know about Tilray's recent performance.

Village Farms International, Inc.(TSX:VFF) (NASDAQ:VFF), one of the Canadian cannabis stocks, after Thursday’s closing bell reported strong first-quarter results, with both its top line and bottom line witnessing solid growth, aided primarily by a notable performance from its 50%-owned Pure Sunfarms joint venture. Consolidated revenues jumped 26% to US$37.3 million for the quarter with Pure Sunfarms contributing US$5.4 million. Consolidated EBITDA for the first quarter came in at US$1.3 million compared to US$1.8 million in the prior-year quarter.